Disialoganglioside directed immunotherapy of neuroblastoma.
about
Molecular recognition of gangliosides and their potential for cancer immunotherapiesIn silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive TumorsHigh-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.Immune-based therapeutics for pediatric cancer.Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.Immunotherapy of childhood cancer: from biologic understanding to clinical application.Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.Therapeutic targets for neuroblastomas.Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastomaAnti-Neuroblastoma Activity of Gold Nanorods Bound with GD2 Monoclonal Antibody under Near-Infrared Laser IrradiationDetection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer.Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology.Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid.Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionMagnetic Nanoparticles: Material Engineering and Emerging Applications in Lithography and Biomedicine.Immune response to racotumomab in a child with relapsed neuroblastoma.Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.Dinutuximab and PanobinostatRESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY.Immunotherapeutic strategies to target prognostic and predictive markers of cancer.Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.Pre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma.State of the art in anti-cancer mAbs.Pharmacotherapy of neuroblastoma.Radioimmunotherapy of solid tumors: searching for the right target.Treatment of high-risk neuroblastoma with anti-GD2 antibodies.Neuroendocrine cancer vaccines in clinical trials.Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.Development of treatment strategies for advanced neuroblastoma.Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.Nanomedicine as an innovative therapeutic strategy for pediatric cancer.Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine.Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model.Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response.
P2860
Q26830588-6AA4FBD4-A5FC-4C9B-8FFB-3AE08D2A3B0BQ27678257-2C8A6BB9-0B02-4748-8D11-1898EAFFC300Q33392673-3BDCD648-864D-434F-891F-680346176B3EQ33604121-31331F34-08EF-49A8-AD7A-584A60F9E2BFQ33659849-E730C545-453C-47F4-B6BF-4AFD244A0DA4Q33752982-B0CE2ACC-947F-4D01-A835-64078276F336Q34389202-C2964770-61F0-4DC9-B911-E6774189FFAEQ34560877-B23C90C3-03BB-4D70-9AD8-56A546532842Q34939364-1865791F-0394-4629-ABC9-C8929210EE30Q35038011-6988DDD9-DFF6-4A46-83F3-C308CB05E3FDQ35224101-5C492C03-D699-49BA-AA83-65C56F844277Q35255233-1BF22178-A880-4153-9E62-AA24A53D738FQ35721147-2295A12F-C0FC-4FB9-9ACA-9747B0A171E2Q35739810-D3A4C746-52AE-4D53-A54B-6949DA13B756Q35752673-C2E1D68F-94DA-4E6D-AA50-47F19E7BDFBCQ35963440-53B86EAB-EB58-49C4-A72A-73E318D09908Q36157472-64D9E509-CE0A-4B18-9324-9D0C7216CBB3Q36212437-C75FE5F2-9689-44B0-9DF5-7E49ABB08876Q36283461-FB87BDF4-E55F-4DE4-8379-98EF745BBA4DQ36479182-D2B7A587-E780-452C-91BB-B85933FEE443Q36564275-DFDFCE50-CEBA-414F-8B26-B1C78E9C1BE3Q36572408-2B0310B2-18B6-41B4-8D9B-954B38EA5A14Q36776358-D07C7993-0A4B-4046-912C-17C13AC0E1EAQ37126006-FF915AAA-09C0-4E88-9F67-E6BEE8DB331AQ37139002-F3D739EA-2A28-403D-A3A7-D05D222C9805Q37220750-213817A1-C684-4246-9A1C-99A15780CC62Q37475635-C0AEFDC7-0E62-4BC9-A50C-01EDC471D332Q37655585-FF880741-65A6-4E67-952F-F8493B976FBEQ37735199-741781D6-E5A6-46DA-97C3-53A3563C11B8Q37804904-7EBF5259-B77A-429B-AC3C-BDF902E0A4A3Q37820755-35412D4C-8C6A-424E-99FD-9ED4CF1E10F6Q37892589-A47E1607-229C-41E7-BCC3-2B19987698CFQ37974938-00139538-83CE-47A2-B84B-F97BEEA7980DQ38010377-7FB9A48D-301C-403E-8E87-0E02BABC3618Q38079519-B00D9F1E-0B40-41E4-963A-23BB5BF6572FQ38359099-BFA7B208-53FD-452D-80D1-FEF386AD436BQ38474631-50757325-FEFF-437E-BE24-57C2E6C01B42Q38751090-915C6798-8AAE-46D2-A5A1-796191B98816Q39155565-61741A92-7CA7-4C0E-A468-C7E6D0167953Q39165145-82358DE9-E3D9-4E01-9412-A78BDDCB3809
P2860
Disialoganglioside directed immunotherapy of neuroblastoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Disialoganglioside directed immunotherapy of neuroblastoma.
@ast
Disialoganglioside directed immunotherapy of neuroblastoma.
@en
type
label
Disialoganglioside directed immunotherapy of neuroblastoma.
@ast
Disialoganglioside directed immunotherapy of neuroblastoma.
@en
prefLabel
Disialoganglioside directed immunotherapy of neuroblastoma.
@ast
Disialoganglioside directed immunotherapy of neuroblastoma.
@en
P2860
P1433
P1476
Disialoganglioside directed immunotherapy of neuroblastoma.
@en
P2093
Nai-Kong V Cheung
Shakeel Modak
P2860
P356
10.1080/07357900601130763
P577
2007-02-01T00:00:00Z